Position in URGN
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$523,146
-$181,702 QoQ
Shares Held
29,096
-3.3% QoQ
Ownership
0.060%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in URGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Cetera Investment Advisers holds $158,169,500 across 104 Biotechnology names. URGN ranks #47 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
72,633 | $32,433,539 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
16,006 | $12,366,875 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
23,173 | $7,667,250 | |
| 4 | EXEL |
Exelixis, Inc.
|
169,881 | $7,286,196 | |
| 5 | IBRX |
ImmunityBio, Inc.
|
946,709 | $7,261,258 | |
| 6 | OCUL |
Ocular Therapeutix, Inc
|
764,615 | $6,476,289 | |
| 7 | VKTX |
Viking Therapeutics, Inc.
|
189,028 | $6,150,971 | |
| 8 | INSM |
INSMED Inc
|
34,356 | $5,617,893 |
All Filings in URGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $523,146 | 29,096 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $704,848 | 30,096 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $640,315 | 32,096 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $361,269 | 26,370 | Shares | Sole | 2025-08-08 | |
| No filing history on record for this holder in this stock. | ||||||